- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc stock price live, this page displays NASDAQ PHAT stock exchange data. View the PHAT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Phathom Pharmaceuticals Inc real time stock price chart below.
What Is the Phathom Pharmaceuticals Inc Stock Price Today?
The Phathom Pharmaceuticals Inc stock price today is 8.51.
What Is the Stock Symbol for Phathom Pharmaceuticals Inc?
The stock symbol for Phathom Pharmaceuticals Inc is "PHAT."
What Stock Exchange Does Phathom Pharmaceuticals Inc Trade On?
Phathom Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Phathom Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Phathom Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHAT quote. (ISIN: US71722W1071)
What Is the Phathom Pharmaceuticals Inc Stock Price Today?
The Phathom Pharmaceuticals Inc stock price today is 8.51.
What Is the Stock Symbol for Phathom Pharmaceuticals Inc?
The stock symbol for Phathom Pharmaceuticals Inc is "PHAT."
What Stock Exchange Does Phathom Pharmaceuticals Inc Trade On?
Phathom Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Phathom Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Phathom Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHAT quote. (ISIN: US71722W1071)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.47
8.82
52 wk Range
8.21
18.31
PHAT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.478.82
52 wk Range
8.2118.31
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHAT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
21.90
Upside
+157.34%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading near 52-week low
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 21.90
(+157.34% Upside)
Phathom Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- Q2 revenue hit $74.3M, up 88% YoY, beating estimates; achieved positive operating profit ex-stock comp one quarter early.
- Generated $1.6M cash from operations for first time; ended quarter with $182.5M cash and 2.21 current ratio for liquidity.
- Full-year 2026 revenue guidance refined to $310M-$325M from payer friction; shares fell 8.93% premarket to $10.60 despite beat.
- Phase II eosinophilic esophagitis data expected Q4 2026; phase III as-needed VOQUEZNA trial planned Q4 with label expansion eyed for 2029.
- CEO Basta cited pivot to GI-focused model; sees $1B annual revenue potential, with second $1B possible via future primary care expansion.
Last Updated: 2026-07-30, 09:16 a/m
Read Full TranscriptEarnings
Latest Release
Jul 30, 2026
EPS / Forecast
-- / -0.19
Revenue / Forecast
74.27M / 73.98M
Compare PHAT to Peers and Sector
Metrics to compare | PHAT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHATPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.8x | −15.5x | −0.4x | |
PEG Ratio | −0.09 | −0.32 | 0.00 | |
Price/Book | −2.0x | 1.2x | 2.6x | |
Price / LTM Sales | 2.8x | 1.9x | 3.1x | |
Upside (Analyst Target) | 150.9% | 51.6% | 48.2% | |
Fair Value Upside | Unlock | −3.1% | 5.8% | Unlock |
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Phathom Pharma (PHAT) Stock Price Today?
The Phathom Pharma stock price today is 8.51 USD.
What Stock Exchange Does Phathom Pharma Trade On?
Phathom Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Phathom Pharma?
The stock symbol for Phathom Pharma is "PHAT."
What Is the Phathom Pharma Market Cap?
As of today, Phathom Pharma market cap is 675.95M USD.
What Is Phathom Pharma's Earnings Per Share (TTM)?
The Phathom Pharma EPS (TTM) is -1.27.
When Is the Next Phathom Pharma Earnings Date?
Phathom Pharma will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is PHAT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Phathom Pharma Stock Split?
Phathom Pharma has split 0 times.
How Many Employees Does Phathom Pharma Have?
Phathom Pharma has 371 employees.
What is the current trading status of Phathom Pharma (PHAT)?
As of Aug 11, 2026, Phathom Pharma (PHAT) is trading at a price of 8.51 USD, with a previous close of 8.57 USD. The stock has fluctuated within a day range of 8.47 USD to 8.82 USD, while its 52-week range spans from 8.21 USD to 18.31 USD.
What Is Phathom Pharma (PHAT) Price Target According to Analysts?
The average 12-month price target for Phathom Pharma is 21.90 USD, with a high estimate of 29 USD and a low estimate of 13 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +157.34% Upside potential.
What Is the PHAT Premarket Price?
PHAT's last pre-market stock price is 8.79 USD. The pre-market share volume is 10.00, and the stock has decreased by 0.22, or 2.57%.
What Is the PHAT After Hours Price?
PHAT's last after hours stock price is 8.50 USD, the stock has decreased by -0.01, or -0.12%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.